For example, the nucleoside cytidine analogue Azacytidine acts as a hypomethylating agent by inhibiting DNA methyltransferases, and is used in the clinic to treat patients with high-risk MDS and AML.18,19 A recent report showed that the Menin inhibitor Revumenib efficiently induced remissions in pediatric and adult AML patients with KMT2A rearrangements or NPM1 mutations.20 These results stand out as they represent the first efficient epigenetic therapy that is based on the eviction of protein complexes from chromatin. The gene discussed is KMT2A; the disease is acute myeloid leukemia.